Treatment
PD-1 inhibitor clinical trials
We’re tracking 199 recruiting studies that include PD-1 inhibitor, each written for real people, not researchers, below.
Recruiting studies
- NCT07007182RecruitingPhase 2
Treating stomach cancer spread to lymph nodes with chemo, surgery, and radiation
This trial tests a combination of chemotherapy (conversion therapy), surgery, and radiation for people with stomach cancer that has spread only to lymph nodes behind the stomach. The goal is to see if this approach can help shrink the cancer and improve outcomes.
Jinan, ShandongAges 18–75 - NCT07523737RecruitingPhase 2
Combination drug trial for relapsed brain lymphoma
This trial tests three drugs together—pomalidomide, an anti-PD-1 antibody, and selinexor—to treat primary central nervous system lymphoma (a blood cancer in the brain) that has returned after previous treatment. The goal is to see if this combination can shrink the cancer and help patients live longer.
Beijing, Beijing MunicipalityAges 18–75 - NCT07555678RecruitingPhase 2
Chemotherapy, radiation, and immunotherapy for anal cancer
This study tests a combination of chemotherapy, radiation therapy, and an immunotherapy drug (anti-PD-1 antibody) for anal squamous cell cancer. The trial enrolls patients at different stages of disease to see if adding immunotherapy improves outcomes.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07100405Recruiting
TACE plus Immunotherapy for Advanced Liver Cancer
This trial tests a combination of two treatments for advanced liver cancer: TACE (a procedure that blocks the blood supply to the tumor) and an anti-PD-1 antibody (a type of immunotherapy that helps your immune system fight cancer). The goal is to see if this combination works better than either treatment alone and to understand how it affects the immune system around the tumor.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06549855Recruiting
PD-1 inhibitor plus progesterone for fertility preservation in MMRd endometrial cancer
This trial tests a combination of an immunotherapy drug (PD-1 inhibitor) and progesterone hormone therapy to treat early-stage, MMR-deficient endometrial cancer while preserving fertility. It may help young women who want to keep the option to have children in the future.
Beijing, Beijing MunicipalityAges 18–45 - NCT06550921Recruiting
Ablation plus lenvatinib and immunotherapy for advanced liver cancer
This trial tests whether adding a targeted procedure (ablation) to burn away cancer spots, when combined with lenvatinib and an immunotherapy drug (PD-1 inhibitor), can help control liver cancer that has spread to a few places. It's for people whose liver tumors are already responding to treatment.
Beijing, None SelectedAges 18–75 - NCT05916248RecruitingEarly Phase 1
mRNA vaccine plus pembrolizumab for advanced solid tumors
This trial tests whether a personalized mRNA vaccine, given with pembrolizumab, can help people with advanced solid tumors by training the immune system to recognize cancer. It is mainly for patients whose tumor tissue matches specific genetic and immune patterns, and who meet key safety and infection requirements.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05563012RecruitingPhase 2
Short radiation plus chemo and PD-1 immunotherapy for stomach cancer
This Phase 2 trial tests whether giving a short course of radiation before surgery, along with chemotherapy and a PD-1 immunotherapy drug, can improve treatment outcomes for locally advanced stomach cancer. It may help shrink the tumor before surgery and strengthen the immune system’s attack on cancer.
Wuhan, HubeiAges 18–75 - NCT06841679RecruitingPhase 2/Phase 3
Testing utidelone plus chemo for untreated stomach cancer
This trial tests a new capsule (utidelone) combined with standard chemotherapy as a first treatment for advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. It aims to see if this combination works better than current options.
Hialeah, FloridaAges 18 years+ - NCT07185243Recruiting
Study of virus injection plus immunotherapy for advanced solid tumors
This study tests a new combination treatment: a modified virus (hV01) injected directly into a tumor, plus a drug that helps your immune system attack cancer cells (PD-1 inhibitor). It is for people with advanced solid tumors that have not responded to standard therapies.
Xiamen, FujianAges 18–75 - NCT07126119RecruitingPhase 2
Immunotherapy plus chemo before surgery for upper tract cancer
This trial tests whether combining the immunotherapy drug tislelizumab with the chemotherapy drug nab-paclitaxel before surgery can help treat high-risk upper tract urothelial cancer. The goal is to shrink the tumor and improve outcomes for patients who are planning to have their kidney and ureter removed.
Tianjin, Outside U.S.Ages 18 years+ - NCT06947694RecruitingPhase 2
Testing radioimmunotherapy combinations for lung cancer with metastases
This trial explores whether combining radiation therapy with immunotherapy can trigger an immune response that shrinks tumors throughout the body (abscopal effect) in people with non-small cell lung cancer that has spread to 3 to 6 other sites. It tests different patterns of these treatments to see which works best.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT06561308RecruitingPhase 2
Immunotherapy plus chemo for advanced endometrial cancer
This trial tests a combination of a PD-1 inhibitor (a type of immunotherapy) with chemotherapy given before surgery for advanced endometrial cancer. The goal is to see if this approach helps shrink the tumor and improve outcomes.
Hangzhou, ZhejiangAges 18–75 - NCT07171606RecruitingPhase 2
Study of a new drug for advanced lung cancer
This trial tests a new drug called SSGJ-706, either alone or with other treatments, for people with advanced non-small cell lung cancer (NSCLC) that has spread or cannot be surgically removed. The goal is to see if it helps shrink or control the cancer.
ShanghaiAges 18–75 - NCT07235319RecruitingPhase 3
Immediate vs delayed radiation after chemo-immunotherapy for metastatic NPC
This trial tests whether giving radiation therapy to the main tumor right after chemo-immunotherapy is better than waiting until the cancer comes back, in people with newly diagnosed metastatic nasopharyngeal cancer. It aims to see which approach helps you live longer and have fewer side effects.
Guangzhou, GuangdongAges 18–70 - NCT07233252RecruitingPhase 2
Tislelizumab and chemotherapy for kidney pelvis cancer
This trial tests a combination of an immunotherapy drug (tislelizumab) and a chemotherapy drug (nab-paclitaxel) to treat kidney pelvis cancer while trying to save as much kidney function as possible. It may be an option if you have a small tumor in the kidney pelvis and are scheduled for a laser procedure.
Tianjin, Outside U.S.Ages 18 years+ - NCT07072351RecruitingPhase 1/Phase 2
Radiation plus chemoimmunotherapy for gastroesophageal junction cancer
This trial tests a shorter course of radiation combined with chemotherapy and immunotherapy to shrink gastroesophageal junction cancer before surgery. It aims to make the tumor removable and improve outcomes.
Xiamen, FujianAges 18 years+ - NCT06963814RecruitingPhase 1
HC006 with a PD-1 inhibitor for advanced solid tumors
This trial tests a new drug called HC006 combined with a standard immunotherapy (PD-1 inhibitor) for people with advanced solid tumors. It aims to see if the combination is safe and effective.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06477991Recruiting
No surgery after immunotherapy for MSI-H colorectal cancer
This trial is studying whether some people with a specific type of advanced colorectal cancer (MSI-H/dMMR) might be able to skip surgery after immunotherapy. Doctors will use a blood test (MRD monitoring) to track the cancer, and then decide whether to keep an eye on it or operate.
Kunming, YunnanAges 18–75 - NCT06151743RecruitingPhase 2
Testing drug combo before throat cancer surgery
This trial tests a new combination of drugs (an immunotherapy called a PD-1 inhibitor, cetuximab, and platinum chemotherapy) given before surgery for advanced throat cancer that requires removing the voice box. The goal is to see if this treatment shrinks the tumor and improves outcomes.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06391190RecruitingPhase 1/Phase 2
Chemoradiation plus immunotherapy for advanced cervical cancer
This trial tests combining standard chemoradiation with a PD-1 inhibitor (a drug that helps your immune system fight cancer) for advanced cervical cancer that hasn't been treated yet. The goal is to see if this combination works better than standard treatment alone.
ShanghaiAges 18–75 - NCT07518979RecruitingPhase 2
EGFR-targeted drug plus immunotherapy for advanced penile cancer
This trial tests a new combination treatment for advanced penile cancer that hasn't been treated before. It combines a targeted drug (becotatug vedotin) designed to attack cancer cells with an immunotherapy drug (pucotenlimab) that helps your immune system fight cancer.
Chengdu, SichuanAges 18 years+ - NCT03259867RecruitingPhase 2
TACE plus immune therapy for liver or stomach cancer
This trial tests a combination treatment using a targeted liver procedure plus an immune “checkpoint” medicine to slow cancer growth. It may help people with advanced liver cancer (HCC) or metastatic stomach cancer when standard treatments have not worked.
Orange, CaliforniaAges 18–80 - NCT04785196RecruitingPhase 1/Phase 2
Testing an MDM2 drug plus an immune therapy for advanced tumors
This trial tests APG-115 together with a PD-1 immune therapy in people with advanced liposarcoma or other advanced solid tumors. It may help by blocking tumor growth through a mix of direct tumor targeting and immune system activation.
Guangzhou, GuangdongAges 18 years+
Common questions
- Are there clinical trials studying PD-1 inhibitor?
- Yes. Clin2 currently lists 199 recruiting studies that include PD-1 inhibitor, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a PD-1 inhibitor trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is PD-1 inhibitor an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether PD-1 inhibitor or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.